EPAS1 and neoplasm: Fourth, as VHL disease is attributed to underlying pathogenic hereditary gene alterations targetable by belzutifan therapy, the application of a tumor ‘interception’ strategy with therapeutic HIF2α inhibition in patients with known genetic predisposition, but without prevalent VHL disease-associated manifestations, is highly attractive [53,54].